Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Recipharm AB","sponsor":"Bial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Recipharm AB"},{"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Provides a Regulatory Update on EMA Process for Nefecon","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Calliditas Therapeutics AB"},{"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical receives IND approval for US trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sedana Medical"},{"company":"Lobsor Pharmaceuticals","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STADA Expands Specialty Footprint Through Acquisition of Innovative Therapy for Treating Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lobsor Pharmaceuticals"}]

Recipharm AB

Contact Supplier

Brightest Minds in the CDMO industry - From early Development to Commercial Manufacturing

Contact Supplier

Contact Supplier

Digital Content

BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API

Details:

The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.

Lead Product(s): Opicapone

Therapeutic Area: Neurology Product Name: Ongentys

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Bial

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 01, 2020

Recipharm Company Banner

CPhI Worldwide 2022

Booth # 90J30

envelop Contact Supplier

Calliditas Therapeutics AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Calliditas Provides a Regulatory Update on EMA Process for Nefecon

Details:

In review of marketing authorisation application (MAA) for NEFECON, the CHMP has informed that they will issue an additional list of questions related to manufacturing-related information which will result in the opinion from EMA slipping into the second quarter.

Lead Product(s): Budesonide

Therapeutic Area: Neurology Product Name: Nefecon

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 22, 2022

ASK
US

Upload
your Pipeline Activity

Sedana Medical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sedana Medical receives IND approval for US trials

Details:

Company received IND clearance from the USFDA to initiate phase III pivotal clinical trials with its combination registration of medical device Sedaconda ACD and pharmaceutical Sedaconda (isoflurane) for sedation of mechanically ventilated intensive care patients.

Lead Product(s): Isoflurane

Therapeutic Area: Neurology Product Name: Sedaconda

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 23, 2021

ASK
US

Upload
your Pipeline Activity

Lobsor Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

STADA Expands Specialty Footprint Through Acquisition of Innovative Therapy for Treating Advanced Parkinson’s Disease

Details:

By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.

Lead Product(s): Levodopa,Carbidopa,Entacapone

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: STADA Arzneimittel

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition October 02, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY